Benzinga | Aug 3, 2021 07:05AM EDT

Mizuho Maintains Neutral on Corvus Pharmaceuticals, Lowers Price Target to $3.5

Mizuho analyst Mara Goldstein maintains Corvus Pharmaceuticals (NASDAQ:CRVS) with a Neutral and lowers the price target from $4 to $3.5.